Amarin Corp PLC Stock Price - AMRN

👍️0

Jasbg 8 hours ago Irish, Think you might just be right here. ----------------------------------- Remember - some weeks back - he spins a story of 'his wife working from home' - him "accidently overhearing" - a talk with a patient of his wife - with no luck trying to defend the 'price for Vascepa' compared to a Statin. His 'usual' - every chance placing needles in the confidence and trust in Amarin and Vascepa - this 'imaginary patient conference of his wife' - a little over the top in spinning - for anyone on this board to believe !

👍️0

Whalatane 16 hours ago JR. These are probably contractually required shipments . In previous CC's they had mentioned they were renegotiating their supply contracts and paying a penalty to reduce the size of these contracts . As you know they have a category labelled long term inventory which will be important to chk at next ER Kiwi

👍️0

CaptBeer 16 hours ago Opps, broken link. I'll try again.

👍️0

JRoon71 17 hours ago DMC, what is the significance of your post regarding Paris Panayiotopoulos? Is there an affiliation with Amarin?

👍️0

JRoon71 17 hours ago Capt, true. But at 03/31 we had $325 Million in inventory (at cost). That's close to $1B in gross revenue worth of inventory (at current pace, roughly 4 years worth of inventory). And this is at a moment of declining revenues (though volume may be flat, pricing is just down). So placing ANY orders right now should raise eyebrows. The answer may be very simple. It could be that these shipments are eventually destined for other locations. I don't know if the inventory that Amarin CURRENTLY holds is ever redirected to other countries, or if once warehoused here, it does not get re-distributed. In other words, they might only want to ship FRESH inventory to other countries (if this is in fact what the orders are for). The other answer could be that these are contractually required shipments, and we don't have a choice but to accept them.

👍️0

JRoon71 17 hours ago PL, thanks for that. Couple things: 1. Denner is not an officer or Director. Sarissa (as a company) is not an office or director. Sarissa/Denner is also not yet a 10% shareholder ("Insider"). 2. Since Sarissa/Denner is not yet an "insider", they are not subject to those limitations of shorting (Section 16). A lot of this is "technicalities". Obviously Denner has full access to all inside information. But for purposes of Section 16, and with regards to reporting, they are not yet subject to those limitations. The reporting requirement for 1%+ changes in ownership DO require disclosure because they are a 5%+ owner. This is just how I interpret those rules. I may be wrong.

👍️0

CaptBeer 19 hours ago The last recorded VASCEPA TRx weekly (Nov 30, 2023) value was around 65,000 scripts. 425,000 scripts is only 6.5 weeks supply.

👍️0

Number sleven 20 hours ago Pdude, The shipping information gives us the weight, and the fact that the product was encapsulated. I don't know if they were shipped in bottles or not. At the moment I am assuming that the weight reported is that of the product shipped. Sleven,

👍️0

Pharmacydude 20 hours ago NS 425,166 bottles of V doesn’t make logical sense. A shipping company would only want to know the gross weight a client wants to ship when calculating the shipping charge , weight distribution and fuel needed for the ship. They don’t care about the weight of the product. AI says “The weight of a 40-foot transatlantic shipping container with built-in heating and cooling systems can vary depending on the specific make and model. However, a standard 40-foot refrigerated container, commonly known as a "reefer" container, typically weighs around 8,500 to 10,000 pounds (approximately 3,860 to 4,536 kilograms) when empty. This weight includes the built-in refrigeration unit and insulation.” The question is how many of these 4500 kg shipping containers were used ? if one was so motivated, they could measure the height and diameter of a 120 capsule bottle and then calculate how many bottles would fit on a shipping pallet. Then calculate how many pallets fit in a 40 foot reefer container. Then calculate the total mass of these pallets of V. This would give you an idea of how many shipping containers were used then you could figure out a very rough estimate of how many actual bottles were sent. I don’t have a full bottle of V to measure otherwise AI would figure this out pretty quickly. Come to think of it, AI can probably tell you the height and diameter of a bottle of V. Bottom line is that Amarin did not import 425,000 bottles,

👍️0

DMC8 1 day ago Insights on May 10 and Jun 20 dockets, and your views on them. Thanks.

👍️0

ProLiberty 1 day ago As a 5%+ 13D filer (I think Sarissa owns over 8%) they are required to file on any 1% change up or down (now within 5 days). Sarissa actually has a 2 day reporting requirement given BOD control by Sarissa employees. They would apparently be required to forfeit any profits from short term trades within 6 months to the company: Transaction reporting by officers, directors and 10% shareholders "Section 16 of the Exchange Act applies to an SEC reporting company's directors and officers, as well as shareholders who own more than 10% of a class of the company's equity securities registered under the Exchange Act. The rules under Section 16 require these “insiders” to report most of their transactions involving the company's equity securities to the SEC within two business days on Forms 3, 4 or 5. Section 16 also establishes mechanisms for a company to recover "short swing" profits, or profits an insider realizes from a purchase and sale of the company’s security that occur within a six-month period. In addition, Section 16 prohibits short selling by insiders of any class of the company's securities, whether or not that class is registered under the Exchange Act." https://www.sec.gov/education/smallbusiness/goingpublic/officersanddirectors https://www.pillsburylaw.com/en/news-and-insights/sec-rule-changes-shareholder-ownership-reporting.html

👍️0

DAR53 2 days ago NS, and I don't recall past purchases but have they purchased in the excapsulated form in the past? I do recall the drums of API in the past from your prior posts showing API purchased by various GV providers and Amarin.

👍️0

Number sleven 2 days ago Caddie, I believe that they announced the termination of that project a few quarters back. Sleven,

👍️ 1

DMC8 2 days ago Paris Panayiotopoulos

👍️0

Number sleven 2 days ago DAR, The thing that interests me most is the fact that it's encapsulated. In refrigerated drums, I don't think the API has a shelf Life. Once encapsulated I think it's three years. Sleven,

👍️0

DAR53 2 days ago Thanks NS. Interesting purchases. I wonder if these are precommitted contractually obligated purchases or looking ahead to EU coming on line?

👍️0

caddiedad 2 days ago Maybe this product is for the anticipated combo pill and then it will be encapsulated? Might be wishful thinking on my part, but something has to change in our favor this year.

👍️ 1

DAR53 2 days ago Thanks Jasbg. I had not seen that version. It was an awsome and inspiring version. We certainly need during these troubled times in the USA. It's interesting that a board member from Denmark posted this. Thank You! May God Bess the USA. and Amarin. GLTAL

👍️ 1

Restingzebra 2 days ago Thank you M. As always much appreciate your sage input. Hope all is well.

👍️ 1

Number sleven 2 days ago TCI1, Take note of the state of the shipped product. It's pre encapsulated. That's new we usually receive drums. In the middle of something right now. I'll get back to you about infringement and damages. Check out GSK v Teva. Sleven,

👍️ 2

DMC8 2 days ago Reflection… https://www.cnbc.com/2022/01/29/amarin-has-a-big-decision-to-make-how-sarissa-capital-can-help-it-move-forward.html?__source=iosappshare%7Ccom.google.chrome.ios.OpenExtension

👍️ 1

TCI1 2 days ago Sleven, thanks for keeping us updated with the IPE shipments. It would be great if the generics viewed the recent opinion as potentially exposing them for inducement to infringe the CV patents, thereby dissuading the generics from purchasing and selling their generic version for CV. Any triple damages would only apply to Hikma’s infringement I presume so there needs to be a big enough threat to stop the others from filling the gap. Let’s hope the generics’ lawyers see “clear expression or other affirmative steps” that foster infringement the same we some of us do. It’s interesting to note too that the opinion specifically referred to Hikma’s position that “inferred infringement” is not a breach of the patent act, that Amarin had to prove active infringement. The generics are essentially saying, and I think the court recognises, that yes there is infringement but nothing to do with us. Let’s hope the balance of the Hatch Waxman act turns in our favour.

👍️0

Number sleven 2 days ago https://www.seair.co.in/us-import/product-icosapent-ethyl.aspx Sleven,

👍️0

Whalatane 2 days ago Gr8 track thx Kiwi

👍️0

Monk4444 2 days ago Den Totally agree. What is your BO range expectation? TIA

👍️0

Jasbg 2 days ago Whala, Will this be aloud to stand - as a result of the 2020- 21 World wide virus attack. -------------------------------- Juli 4. coming up - a great tribute to your big Country - of combined very different States 🙂

👍️ 1

Number sleven 2 days ago If anyone has access to the order issued today, I would appreciate seeing it. Thanks. Sleven,

👍️ 1

Number sleven 2 days ago https://www.courtlistener.com/docket/59859757/dr-reddys-laboratories-inc-v-amarin-pharma-inc/ Sleven,

👍️0

Whalatane 2 days ago Jas. You know what day it is ...do you're thing Kiwi

👍️0

couldbebetter 2 days ago GJK, That is an interesting proposition. Perhaps the animosity between the two companies is such that they would never negotiate in a friendly manner. Also, if Hikma were to acquire AMRN maybe Hikma might be sued on anti-trust grounds. My view remains that AMRN should be bought by a Eurocentric BP that could turn Vaskepa into a billion dollar plus product in Europe. NVO, AZN, and Bayer would each be excellent candidates to acquire AMRN. Of course, it is all up to Alex Denner to get this done. Alex controls the BOD so win or lose its all on him. Vascepa is too good a drug to just let it go to waste... But only a BP BO will change the trajectory.

👍️ 1

Jasbg 2 days ago JR, Every pro Day Trader 'Shorts' - every pro HF 'Shorts' - it is part of the game in the HF finance money world - given where Amarin stock is' at the moment. ------------------------------ What is important to remember here is - that a HF like Sarissara can/could invest 'in whatever stock in the marked - and 'Short' - if they felt it were 'best investment plan. ------------------------------ This is NOT what Sarissa and Denner have done around Amarin. There is clearly a long term strategy and plan - in using the effort and energy in taking on KM and 'old board' in the Proxy fight. Truth is' where Amarin are' after the Du-disaster' (opening the door for FREE - for every aggressive generic company) - we couldn't have hoped for a better situation - than Sarissa and Denner taking over.

👍️0

GJK 2 days ago I hadn't looked at the board for 3 days so am catching up on the Hikma reversal and all the questions raised. I've only posted a handful of times in the past; thinking outside of the box, (and I'm not a buyout expert) IF Hikma thinks they will lose the case with potential damages of $1B or more, wouldn't it be easier/smarter for them to just buy AMRN? Buying AMRN would remove paying damages, acquiring the patents on the CVD indication AND the IPE inventory held by AMRN and then be able to sell into the CVD population in addition to SHTG. They would also have Europe locked up and they would have the assets to do what I believe a BP would do and find additional indications to sell into. I don't know what that would translate into cost per share wise for a BO but given the current share price, the stock buyback (and assumes some 3rd party may already have purchased some/all of the 50 million shares before this happens), I think the vast majority of shareholders would gladly take something in $7-$15 rangeand be glad to be done with the company (I know I would as I have held this stock since 2016 or so). Full disclosure, I take Vascepa and believe it has extended my life following quadruple bypass and TCO (Total Coronary Occlusion) of 3 of my grafts. I currently own approximately 50K shares at average cost $3.20 or so.

👍️0

JRoon71 2 days ago PL, saying it is nonsense, is nonsense, given the fact that they STATED in their proxy that they may short the stock. And the fact that they have made virtually no public statements to defend their product in 18 months. I’m not necessarily saying shorting is wrong for them to do. They told us all in advance that they might. And it may be doing the job of keeping the SP down for the time being so they can buy back low. If we see Sarissa start buying more, the short ratio starts to shrink, and the SP begins moving up, as well as PR’s start flying, it’s a pretty good sign that they’ve been shorting. In a way, it might end up being the right move. This stock NEEDS momentum to fly. And I think they have been intentionally holding it back so that they can build momentum around multiple catalysts at the same time.

👍️0

Nukemtiltheyglow 2 days ago Excellent job as usual.

👍️0

seve333 3 days ago Well they only shorted it down a cent at the close but this post pretty much sums up denner. Been an absolute fiasco. He will never win anoter proxy again imo. 54m $AMRN End of quarter now, at essentially all time low since Sarissa/Denner took over. Three ceo's in last year. The science for this asset is impeccable Denner's management has been on a sleepy Joe scale. What say you, AD?

👍️0

seve333 3 days ago Many people think they are shorting. Watch them drop it two cents agan the close like they do every single day now. They clearly have no interest in seeing the stock price rise at all right now. But then again we dont know anything because they never say a word period. I bet if we tried to proxy them out they would suddenly be talking everyday like drunken sailors.

👍️0

FAQs

Amarin Corp PLC Stock Price - AMRN | ADVFN? ›

Based on analyst ratings, Amarin Corporation Plc's 12-month average price target is $1.00. Amarin Corporation Plc has 41.04% upside potential, based on the analysts' average price target. Amarin Corporation Plc has a consensus rating of Moderate Sell which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.

Read The Full Story ›

Is AMRN a good stock to buy now? ›

View Details ›

Will Amarin stock recover? ›

According to our current AMRN stock forecast, the value of Amarin Corporation plc shares will rise by 1.36% and reach $ 0.710435 per share by July 3, 2024. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).

Learn More Now ›

What is the price target for Amarin? ›

Based on short-term price targets offered by two analysts, the average price target for Amarin comes to $1.00. The forecasts range from a low of $1.00 to a high of $1.00. The average price target represents an increase of 44.93% from the last closing price of $0.69.

Learn More Now ›

What is the dividend yield of AMRN? ›

Historical dividend payout and yield for Amarin (AMRN) since 1971. The current TTM dividend payout for Amarin (AMRN) as of June 14, 2024 is $0.00. The current dividend yield for Amarin as of June 14, 2024 is 0.00%.

Discover More ›

Is Amarin a takeover target? ›

Amarin has a star drug and would be a prime takeover target for Big Pharma.

Get More Info ›

What drugs does Amarin make? ›

VASCEPA is a prescription medicine used:

along with certain medicines (statins) to reduce the risk of heart attack, stroke and certain types of heart issues requiring hospitalization in adults with heart (cardiovascular) disease, or diabetes and 2 or more additional risk factors for heart disease.

Get More Info Here ›

Who owns AMRN stock? ›

The ownership structure of Amarin (AMRN) stock is a mix of institutional, retail and individual investors. Approximately 17.39% of the company's stock is owned by Institutional Investors, 19.72% is owned by Insiders and 62.89% is owned by Public Companies and Individual Investors.

Read The Full Story ›

Who are the shareholders of Amarin? ›

Top Institutional Holders

Holder	Shares	Date Reported
DG Capital Management, LLC	6.44M	Mar 31, 2024
Eversept Partners, LP	6.21M	Mar 31, 2024
Morgan Stanley	3.61M	Mar 31, 2024
Two Sigma Investments, LP	3.39M	Mar 31, 2024

6 more rows

Get More Info Here ›

Who are Amarin competitors? ›

Amarin's competitors

Amarin.
Horizon Therapeutics.
Afimmune.
Matinas BioPharma.
Micelle BioPharma.
Acasti Pharma.

Learn More ›

What does Amarin Corporation do? ›

Amarin is a leading cardiovascular health pharmaceutical company. As leaders, we apply science, research, passion and global knowledge to ensure we further our vision of stopping cardiovascular disease from being a leading cause of death.

Discover More ›

What is the highest stock price target? ›

The all-time high Target stock closing price was 249.25 on November 16, 2021. The Target 52-week high stock price is 181.86, which is 22.8% above the current share price. The Target 52-week low stock price is 102.93, which is 30.5% below the current share price.

See Details ›

What is the price target for visa stock 2025? ›

According to our Visa stock prediction for 2025, V stock will be priced at $ 308.72 in 2025.

Keep Reading ›

Who has the highest dividend yield? ›

Top 100 Highest Dividend Yield ETFs

Symbol	Name	Dividend Yield
NVDQ	T-Rex 2X Inverse NVIDIA Daily Target ETF	109.80%
CONY	YieldMax COIN Option Income Strategy ETF	86.07%
TSL	GraniteShares 1.25x Long Tesla Daily ETF	85.35%
KLIP	KraneShares China Internet and Covered Call Strategy ETF	58.88%

93 more rows

Read On ›

Which oil company has the highest dividend yield? ›

Top oil and gas companies by dividend yield

#	Name	Dividend %
1	Diversified Energy 1DEC.L	22.87%
2	Ecopetrol 2EC	22.01%
3	Petrobras 3PBR	17.54%
4	MOL Group 4MOL.BD	15.91%

57 more rows

Read On ›

Is Bayer a good dividend stock? ›

As of 2023-12-31, Bayer AG's dividend payout ratio is 11.69, which may suggest that the company's dividend is sustainable.

See Details ›

Is BioNano a buy or sell stock? ›

BioNano Genomics Inc's analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

Show Me More ›

What is the future of VTGN stock? ›

VTGN Stock 12 Month Forecast

Based on 1 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $12.00 with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 269.23% change from the last price of $3.25.

View Details ›

Is Novartis a good company to invest in? ›

NVS sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of B. Compared to the Large Cap Pharmaceuticals industry's P/E of 14.5X, shares of Novartis are trading at a forward P/E of 14.5X. NVS also has a PEG Ratio of 1.6, a Price/Cash Flow ratio of 9.5X, and a Price/Sales ratio of 4.4X.

Show Me More ›

What is the stock potential for Novartis? ›

Based on analyst ratings, Nvidia's 12-month average price target is $156.35. Nvidia has 32.38% upside potential, based on the analysts' average price target. Nvidia has a consensus rating of Strong Buy which is based on 38 buy ratings, 3 hold ratings and 0 sell ratings.

Learn More ›

Amarin Corp PLC Stock Price - AMRN | ADVFN (2024)

FAQs

Amarin Corp PLC Stock Price - AMRN | ADVFN? ›

What does Amarin Corporation do? ›